1. Introduction {#s0005}
===============

Cholangiocarcinoma is the second most common primary hepatobiliary malignancy and accounts for over 7000 deaths annually in the United States [@b0005], [@b0010]. Intrahepatic cholangiocarcinoma (ICC) comprises 10% of cholangiocarcinomas.^1^ Complete surgical resection offers the only possibility of cure for these patients, however only 12% of ICCs have resectable disease at diagnosis, accounting for one-third of patients with localized disease [@b0015]. For the remaining patients with localized disease not amenable to surgical resection, several liver-directed treatment options exist, including conventionally fractionated external beam radiation therapy, chemoradiation (CRT), stereotactic body radiation therapy (SBRT), transarterial chemoembolization (TACE), and transarterial radioembolization (TARE) using yttrium-90 microspheres [@b0020], [@b0025].

In part due to the rarity of the disease, there is no randomized evidence to guide decision making with regard to liver-directed therapies for unresectable ICC. Within radiation oncology, CRT has historically been the preferred treatment in the setting of hepatobiliary malignancies [@b0030], [@b0035], [@b0040], [@b0045], but in more recent years SBRT and TARE have emerged as effective, conformal modalities that deliver high doses to tumor while limiting normal tissue toxicity [@b0050]. The former modality employs hypofractionated external beam radiation and stereotactic immobilization, while the latter is a transcatheter intra-arterial procedure (typically performed by interventional radiology) that entails injection of yttrium-90 microspheres into the hepatic artery, thus capitalizing on the differential dependence of malignancy and normal parenchyma on hepatic arterial and portal venous blood supply, respectively. While there are retrospective studies comparing external beam radiotherapy to non-radiotherapeutic modalities [@b0055], there are no studies comparing SBRT to conventional chemoradiation or TARE for this group of patients. We studied the overall survival of patients treated with SBRT, CRT, and TARE using the National Cancer Database (NCDB), a nationwide hospital-based registry accounting for 70% of newly diagnosed cancers in the United States.

2. Materials and methods {#s0010}
========================

2.1. Study population {#s0015}
---------------------

Using the NCDB, we identified patients with histologically- or cytologically-confirmed intrahepatic adenocarcinoma of the biliary tract diagnosed between 2004 and 2014. We included patients no more than 85 years old with a Charlson comorbidity score of 0--2. Patients who received surgery, had metastatic or lymph node-positive disease, or had missing T-stage or tumor size data, were excluded. Only patients who received CRT, SBRT, or TARE were included. SBRT was defined as external beam radiation therapy to a total dose of ≥30 Gy delivered in ≤5 fractions [@b0060]. Patients who were treated with \<5 Gy per fraction with concurrent chemotherapy, defined as chemotherapy initiated within 14 days of radiation start, were allotted to the CRT group. Receipt of chemotherapy during the first line of treatment was permitted in the SBRT and TARE cohorts.

2.2. Statistical analysis {#s0020}
-------------------------

Patient characteristics were summarized by treatment groups using means and standard deviations for continuous variables and frequencies and percentages for categorical variables. Kruskal-Wallis tests were used to compare the differences in continuous variables among the treatment groups, while Chi-square tests or Fisher's exact tests were used for categorical variables. Kaplan-Meier curves were generated and log-rank testing was used to compare the differences in overall survival among the treatment groups. To further study the association between treatment and overall survival, and to adjust for possible confounders, Cox proportional hazard models were used to estimate the hazard ratios between groups. Variables with statistically significant differences in distributiuon between the treatment groups were selected as covariates for Cox proportional hazards. Missing data was handled as a unique level for multivariable analysis. In order to rule out the potential biases from variables that predict for receipt of treatment, age, year of diagnosis, Charlson comorbidity score, vascular invasion, clinical T stage, tumor focality, and tumor size were used to generate propensity scores that were used to calculate inverse probability of treatment weights, which were accounted for in a weighted Kaplan-Meier analysis. Due to the three pairwise comparisons, the Bonferroni adjusted significance threshold was set at p = 0.05/3 = 0.017 for the Kaplan-Meier comparisons of the inverse probability of treatment-weighted cohorts. All statistical analyses were performed using SAS (version 9.4, SAS Institute Inc, Cary, NC).

3. Results {#s0025}
==========

[Fig. 1](#f0005){ref-type="fig"} shows the patient selection schema for the analyzed cohort. There were a total of 141 analyzable patients with unresectable ICC treated with SBRT (n = 27), CRT (n = 54), or TARE (n = 60). [Table 1](#t0005){ref-type="table"} shows the patient and disease characteristics of the cohort. SBRT, CRT, and TARE cohorts were respectively characterized by increasing proportion of patients with vascular invasion and tumor multifocality. ICC treated with TARE, specifically, was characterized by larger tumor size and higher T-stage, as well as more recent year of diagnosis. Roughly half of patients who received SBRT or TARE also received chemotherapy during the first course of treatment. The median dose and number of fractions for CRT was 50.4 Gy (interquartile range \[IQR\] 45--54 Gy) and 28 fractions (IQR 25--30), respectively. The median dose and number of fractions for SBRT was 45 Gy (40--50 Gy) and 5 fractions (IQR 3--5) respectively. Median follow-up time for all patients was 17 months. On univariate analysis, SBRT was associated with higher overall survival compared to CRT (hazard ratio \[HR\] = 0.37; 95% confidence interval \[CI\] 0.20--0.68; p = 0.001) and TARE (HR = 0.40; 95% CI 0.22--0.74; p = 0.003). There was no statistically significant difference in overall survival between patients treated with TARE and CRT (HR = 0.92; 95% CI 0.60--1.40; p = 0.69) ([Fig. 2](#f0010){ref-type="fig"}). The median overall survival for patients treated with SBRT, TARE, and CRT was 48 months (95% CI 20, upper limit not reached), 20 months (95% CI 14--24), and 14 months (95% CI 11--20), respectively.Fig. 1Patient selection schema for the analyzed cohort.Table 1Patient and disease characteristics of the analyzed cohort, stratified by radiotherapeutic modality[\*](#tblfn50){ref-type="table-fn"}.CharacteristicSBRTTARECRTPn (%)27 (100%)60 (100%)54 (100%)  Age (Years) Median (IQR)71 (61, 80)65 (57.5, 74.5)67 (61, 74)0.11[†](#tblfn1){ref-type="table-fn"}  Sex Male18 (66.7%)27 (45.0%)25 (46.3%)0.14[‡](#tblfn2){ref-type="table-fn"} Female9 (33.3%)33 (55.0%)29 (53.7%)  Race White25 (92.6%)51 (85.0%)46 (85.2%) Black1 (3.7%)2 (3.3%)2 (3.7%)0.85[§](#tblfn3){ref-type="table-fn"} Other1 (3.7%)7 (11.7%)6 (11.1%)  Charlson Comorbidity Score 017 (63.0%)41 (68.3%)39 (72.2%)0.35[§](#tblfn3){ref-type="table-fn"} 19 (33.3%)13 (21.7%)14 (25.9%) 21 (3.7%)6 (10.0%)1 (1.9%)  Year of diagnosis Median (IQR)2011 (2008, 2013)2013 (2011, 2014)2010 (2007, 2012)\<0.0001[†](#tblfn1){ref-type="table-fn"}  T-stage 116 (59.3%)18 (30.0%)13 (24.1%) 27 (25.9%)34 (56.7%)15 (27.8%)\<0.0001[§](#tblfn3){ref-type="table-fn"} 33 (11.1%)8 (13.3%)22 (40.7%) 41 (3.7%)0 (0.0%)4 (7.4%)  Tumor Size (cm) Median (IQR)4.5 (3.2, 5.9)6.5 (4.5, 9.2)4.4 (2.9, 6.5)\<0.0001[†](#tblfn1){ref-type="table-fn"}  Vascular Invasion No16 (59.3%)23 (38.3%)12 (22.2%)0.038[‡](#tblfn2){ref-type="table-fn"} Yes7 (25.9%)21 (35.0%)22 (40.7%) Unknown4 (14.8%)16 (26.7%)20 (37.0%)  Tumor Focality Unifocal3 (11.1%)19 (31.7%)3 (5.6%)0.032[§](#tblfn3){ref-type="table-fn"} Multifocal17 (63.0%)34 (56.7%)24 (44.4%) Unknown7 (25.9%)7 (11.6%)27 (50.0%)  Chemotherapy No16 (59.3%)27 (45.0%)0 (0.0%) Yes11 (40.7%)32 (53.3%)54 (100.0%) Unknown0 (%)1 (1.7%)0 (0.0%)\<0.0001[§](#tblfn3){ref-type="table-fn"}[^1][^2][^3][^4]Fig. 2Kaplan-Meier curves for overall survival, stratified by radiotherapeutic modality.

On multivariable analysis ([Table 2](#t0010){ref-type="table"}), SBRT remained associated with higher overall survival when compared to CRT (adjusted HR = 0.44; 95% CI 0.21--0.91; p = 0.028) and TARE (HR = 0.42; 95% CI 0.21--0.84; p = 0.014). There was no statistically significant difference in overall survival with TARE when compared to CRT (HR = 1.04; 95% CI 0.58--1.86; p = 0.89). None of the other covariates tested on multivariable analysis had a statistically significant association with overall survival.Table 2Cox proportional hazards multivariable hazard ratios.[\*](#tblfn4){ref-type="table-fn"}CharacteristicHRLower CIUpper CIPTreatment CRT1.01.01.0-- TARE1.040.581.860.89 SBRT0.440.210.910.028 Year of diagnosis1.030.941.120.57  T-stage 1--21.01.01.0-- 3--41.050.561.960.89 Tumor size (cm)1.000.991.000.31  Vascular invasion No1.01.01.0-- Yes0.880.531.480.64  Tumor focality Unifocal1.01.01.0-- Multifocal1.130.592.190.71  Chemotherapy No1.01.01.0-- Yes0.830.471.430.50[^5]

After excluding patients with missing covariates for propensity weighting, there were 19, 25, and 43 patients in the SBRT, CRT, and TARE cohorts, respectively. After propensity weighting adjustment, SBRT maintained a statistically significant higher overall survival compared to CRT (HR = 0.22; 95% CI 0.11--0.44; p \< 0.0001) and was nominally associated with higher overall survival compared to TARE (HR = 0.58; 95% CI 0.37--0.91; p = 0.019) without reaching the Bonferroni-adjusted significance threshold (ɑ = 0.017). There was again no statistically significant difference in overall survival between patients treated with TARE and CRT (HR = 1.05; 95% CI 0.67--1.63; p = 0.84) ([Fig. 3](#f0015){ref-type="fig"}).Fig. 3Kaplan-Meier curves for overall survival of inverse probability of treatment-weighted cohorts, comparing (A) SBRT to CRT (B) SBRT to TARE and (C) CRT to TARE. Note that risk tables have been excluded due to variable patient weighting.

4. Discussion {#s0030}
=============

In what is, to our knowledge, the first study comparing outcomes of radiotherapeutic modalities for unresectable ICC, we found SBRT was associated with higher overall survival when compared to CRT or TARE. Importantly, these results were similar after adjusting for relevant prognostic and confounding variables, including T-stage, tumor size, focality, and vascular invasion [@b0065], [@b0070], [@b0075].

The rarity of ICC has complicated efforts to prospectively and comparatively evaluate radiotherapy modalities for nonsurgical management of unresectable disease, although several studies have shown promising results for individual techniques. Studies have shown a modest prognostic and palliative benefit to external beam radiation therapy for unresectable ICC [@b0080], [@b0085], [@b0090]. Additionally, multiple studies suggest favorable survival associated with addition of concurrent chemotherapy to radiation for biliary malignancies [@b0030], [@b0035], [@b0040], [@b0045]. Based on these studies, as well as the survival benefit associated with concurrent chemotherapy seen in other gastrointestinal malignancies, including rectal, anal, and pancreatic cancers, addition of chemotherapy to conventionally fractionated radiotherapy is encouraged [@b0025]. More recently, studies have shown that high ablative doses typified by SBRT lead to improved overall survival and local control, irrespective of chemotherapy administration [@b0060], [@b0095], [@b0100], [@b0105], [@b0110]. In tandem, radioembolization using yttrium-90 microspheres has emerged as an effective treatment option, favored for its ability to deliver high dose of radiation with minimal collateral hepatotoxicity [@b0115], [@b0120], [@b0125].

Given the lack of randomized data, the choice of radiotherapy modality is currently made on the basis of various clinical- and tumor-related factors, such as tumor size and location, particularly given that historical comparisons are limited due to the heterogeneity of these variables between studies. Nevertheless, in the absence of factors clearly precluding a specific modality (such as excessive hepatopulmonary shunting when considering TARE), such a framework does little to clarify which modality is associated with superior outcomes. For a 4 cm tumor, for example, TARE, SBRT, or CRT may all be reasonable approaches for management [@b0020].

Our data suggests that SBRT is the preferred modality in the absence of contraindications, such as a prohibitively large tumor size. While it may be argued that these findings reflect the preferential use of SBRT for more limited and less aggressive disease, our findings persisted after adjusting for discrepancies in stage, size, and focality. Furthermore, the survival benefit associated with SBRT when compared to CRT is congruent with studies suggesting survival advantage with dose-escalation in the setting of external beam radiotherapy. A retrospective study of 79 patients treated at MD Anderson Cancer Center showed that treatment of localized inoperable ICC to a biologically equivalent dose (BED) of \>80.5 Gy, when compared to lower doses, was associated with a 3-year overall survival of 73% versus 38% and a 3-year local control of 78% versus 45%. Median overall survival for the entire cohort was 30 months and median overall survival for the high-BED group, specifically, was not reached [@b0060]. Additionally, in a multi-institutional phase II study of high-dose hypofractionated proton beam therapy for ICC and hepatocellular carcinoma, the 37 patients with ICC had encouraging 2-year local control and overall survival of 94.1% and 46.5%, respectively, after treatment with a maximum total dose of 67.5 Gy equivalent in 15 fractions. Median overall survival for the ICC group was 22.5 months [@b0130]. Although we did not explicitly evaluate patients treated with hypofractionated regimens delivered in greater than 5 fractions, in comparison to the aforementioned studies, the SBRT patients in our study had a favorable median overall survival of 48 months. Such comparisons should be interpreted with caution, however, as the SBRT patients in our study have more favorable disease characteristics such as smaller tumor size and no prior therapy.

We also found that SBRT is associated with improved overall survival compared to TARE, a modality that theoretically offers high dose delivery and conformity. Retrospective evidence in the setting of hepatocellular carcinoma suggests that both modalities offer good pathologic response and minimal toxicity as a bridge to transplant [@b0135]. However, although TARE is characterized by a high selectivity for tumor versus normal hepatic parenchyma, and potential to deliver high dose to tumor [@b0140], it is limited by significant variability in absorbed dose [@b0145], [@b0150], [@b0155]. It is unclear if our findings reflect this disadvantage, microenvironment-based resistance that is specific to ICC, superior vascular injury and ablation conferred by SBRT, or unrecognized selection bias. It is also worth noting that novel TARE techniques such as radiation segmentectomy, which permits further dose escalation and conformity compared to lobar infusion, have shown promising results in early-stage hepatocellular carcinoma [@b0160], [@b0165] and may be a comparable alternative to SBRT for limited ICC in the future.

Despite adjustment for key confounders, there are limitations of this study that should be noted. First, the caveats associated with any retrospective study are inherent to this NCDB study, including possible selection bias and inability to account for a variety of potential confounders, such as performance status or departmental/clinical expertise. Along these lines, despite inverse probability of treatment weighting, variability in baseline characteristics such as tumor size and multifocality may reflect potential lead-time bias and/or tumor biology that cannot be accounted for. Second, there is a lack of toxicity data provided for each of the modalities, and baseline liver function may play a role in modality selection and/or radiation dose choice. Furthermore, therapies might be chosen on the basis of anatomic location or radiologic appearance which serve as further confounders in this study. For example, a tumor along the inner edge of the liver might be less likely to receive SBRT due to concern of damaging adjacent bowel, or a tumor with an infiltrative pattern on MRI might be more likely to receive TARE compared to SBRT or CRT since delineating the target may be more difficult or poorly defined. Unfortunately, such detailed data regarding tumor location is not available through NCDB. The lack of dose and microsphere-type data for TARE is also limiting, as biologic effect is known to vary with dose and it is possible that response may vary with microsphere brand [@b0170], [@b0175], [@b0180]. Also, we acknowledge that the statistical power of the study is limited by the relatively low patient numbers in each of the cohorts. Finally, the lack of local recurrence and toxicity data through the NCDB limits complete evaluation of the potential benefit of these modalities. Nevertheless, as the majority of patients with ICC die of tumor-related liver failure, survival is strongly correlated with local control [@b0185].

In summary, we found SBRT was associated with higher overall survival when compared to CRT and TARE in the management of unresectable ICC. These findings suggest that for clinical scenarios amenable to any of these treatments, SBRT may be the preferred option. However, these results should be interpreted with caution given the possibility of selection bias, and these modalities should be compared prospectively to clarify the clinical conditions for which these modalities are best suited.
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[^1]: Abbreviations. SBRT- stereotactic body radiation therapy. TARE- transarterial radioembolization. CRT- chemoradiation. IQR- Interquartile range.

[^2]: Mann-Whitney U (Wilcoxon rank-sum) test.

[^3]: Chi-square test.

[^4]: Fisher's exact test.

[^5]: Abbreviations. HR- hazard ratio. CI- confidence interval. CRT- chemoradiation. TARE- transarterial radioembolization. SBRT- stereotactic body radiation therapy.
